Search bioRxiv⌕ Search

Biology subjects

Costea, D. E.

Publications and source records attributed to Costea, D. E..

2 recordsLinked to original sources

Regulatory T cells modulate bone marrow stromal cell osteogenesis by activating ROCK-myosin axis and cell contractility

Bone regeneration depends not only on the intrinsic signaling in bone marrow-derived mesenchymal stromal cells (BMSC), but also on immune cell-derived cues. Regulatory T cells (Treg) are emerging as immune regulators of tissue repair, yet their direct impact on BMSC osteogenesis remains unexplored. Here, we showed that direct human BMSC-Treg co-culture induced more pronounced osteogenic gene expression and cytokine modulation in BMSC than indirect co-culture. This contact-dependent interaction temporally enhanced BMSC osteogenic gene expression, alkaline phosphatase activity and matrix mineralization by interacting with ROCK-myosin signaling pathway. Exploratory proteomic profiling further revealed enrichment of cytoskeletal, mechanosensitive and osteogenic regulators in BMSC after direct Treg co-culture. Pharmacological inhibition of cell contractility impaired osteogenesis yet Treg co-culture partially restored cytoskeletal integrity and differentiation. These findings identify novel mechanisms behind Treg as direct modulators of BMSC mechanobiology and osteogenesis, highlighting their therapeutic potential in bone regeneration.

cell biology↗

Establishment of a humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

The limited efficacy of immunotherapy in clinical trials in high-grade serous ovarian cancer (HGSOC) may improve by implementing models more reflective of human biology into preclinical studies. To address this, we developed and validated a humanized patient-derived xenograft mouse model of HGSOC. Human hematopoietic stem cells and patient-derived HGSOC were engrafted into immunodeficient mice. The mice were administered durvalumab and/or oleclumab intraperitoneally semi-weekly for five weeks. The immunotherapy was well-tolerated, though no responses occurred. Leukocytes in primary tumors were analyzed immunohistochemically, and circulating T cells were characterized using spectral flow cytometry. All tumors exhibited an immune-excluded immunophenotype. No significant inter-group differences in disease burden, intratumoral leukocyte density, or circulating T-cells were observed. In the durvalumab-only group, tumor burden significantly positively correlated with intratumoral cytotoxic and regulatory T-cell densities. This model reflects human disease biology and clinical findings, providing a robust platform for studying tumor-immune interactions and immunosuppressive mechanisms in HGSOC.

cancer biology↗